Clinical Research Archives | Page 3 of 7

A new North Carolina study called VISION is now underway to answer some of the biggest questions about COVID-19. Led by William Fischer, MD, principal investigator, and David Wohl, MD, co-lead, the study plans to enroll 7,500 COVID-positive individuals to understand the different factors that impact individual risk for key clinical outcomes including recovery from acute illness, symptom rebound, re-infection, and long COVID. Investigators explain the study more in video.

This nationwide clinical trial funded through the National Institutes of Health including participation from patients at the UNC Diabetes Center, led by John Buse, MD, PhD.

The national GRADE study, with leadership and participation from UNC School of Medicine's John Buse, MD, PhD, and Sue Kirkman, MD, found that two of four common type 2 diabetes treatments -- glargine and liraglutide -- worked better than the other drugs, sitagliptin and glimepiride, to maintain blood glucose levels.

UNC School of Medicine’s 55th annual Student Research Day will take place on Friday, Nov. 11. The John B. Graham Research Society is seeking faculty judges to help make the day a success by providing formative feedback to student presenters.

The Women’s Irritability, Stress, and Estrogen Study aims to understand the biological mechanisms underlying the relationship between estrogen changes and increased irritability during the menopause transition.

The Doris Duke Charitable Foundation awarded more than $7.9 million in grants to 16 early-career physician scientists, including two from the UNC School of Medicine – Andrea Knittel, MD, PhD and Peyton Thompson, MD.

The UNC site lead investigators are Michelle Hernandez, MD, professor in the UNC Department of Pediatrics, and Katrina Donahue, MD, MPH, professor and vice chair of research in the UNC Department of Family Medicine.

The Clinical Trials Unit in the UNC Children’s Research Institute is a site for a national study to assess the efficacy of Paxlovid, a pill to treat COVID in children under 18 at increased risk for severe illness.

James F. Howard, MD, Distinguished Professor of Neuromuscular Disease, Professor of Neurology, Medicine and Allied Health in the UNC School of Medicine, was lead investigator in the Phase 3 clinical trial of zilucoplan.

This virtual seminar series will provide a background in the use of machine learning tools to answer clinical questions, understand the strengths and limitations of these methods, and examine real-world examples of machine learning methodology in clinical research. The series is co-sponsored by the UNC Core Center for Clinical Research and the UNC Program for Precision Medicine in Health Care.

Sarah Kowitt, PhD, MPH, Adam Goldstein, MD, MPH, and Samuel Cykert, MD, recently published a study that found a cardiovascular disease risk reduction intervention improved rates of tobacco screening and cessation support in small primary care practices in North Carolina.

James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the ADAPT+ trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.

Category: Clinical Research

UNC Launches Largest COVID-19 Observational Study of its Kind in North Carolina

Bionic Pancreas Improves Type 1 Diabetes Management Compared to Standard Insulin Delivery Methods

Two Popular Diabetes Drugs Outperform Two Others in Head-to-Head Comparison

Student Research Day Judges Needed

WISE Study Seeking Participants for Perimenopausal Research

Knittel, Thompson Receive Clinical Scientist Development Awards

UNC School of Medicine Participating in $31-Million Asthma Study

UNC Children’s Enrolling Participants for Paxlovid Pill Study

UCB Presents Efficacy, Safety Results for Zilucoplan, Rozanolixizumab for Generalized Myasthenia Gravis

Machine Learning Tools for Clinical Researchers: A Pragmatic Approach Event Series

Study Finds Intervention Improved Rates of Tobacco Screening, Cessation Support in Small North Carolina Practices

Interim Data Suggest Long-term Treatment with VYVGART Provides Improvement in Generalized Myasthenia Gravis Disease Scores